Phase II study of the combination of cetuximab and weekly paclitaxel in the first-line treatment of patients with recurrent and/or metastatic squamous cell carcinoma of head and neck-Reference-Cited by-同舟云学术

Phase II study of the combination of cetuximab and weekly paclitaxel in the first-line treatment of patients with recurrent and/or metastatic squamous cell carcinoma of head and neck

Published:2012-04 Issue:4 Volume:23 Page:1016-1022
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Hitt R.,Irigoyen A.,Cortes-Funes H.,Grau J.J.,García-Sáenz J.A.,Cruz-Hernandez J.J.

Publisher

Elsevier BV

Subject

Oncology,Hematology

Link

http://academic.oup.com/annonc/article-pdf/23/4/1016/13785874/mdr367.pdf

Reference34 articles.

1. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008;Ferlay;Int J Cancer,2010

2. An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer;Adelstein;J Clin Oncol,2003

3. Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer;Forastiere;N Engl J Med,2003

4. Cisplatin and 5-fluorouracil infusion in patients with recurrent and disseminated epidermoid cancer of the head and neck;Kish;Cancer,1984

5. Changing role of chemotherapy in treatment of head and neck cancer;Mead;Am J Med,1982

Cited by 189 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Exploring the Therapeutic Implications of Co-Targeting the EGFR and Spindle Assembly Checkpoint Pathways in Oral Cancer;Pharmaceutics;2024-09-11

2. Deciphering the impact of STAT3 activation mediated by PTPRT promoter hypermethylation as biomarker of response to paclitaxel‐plus‐cetuximab in patients with recurrent or metastatic squamous cell carcinoma of the head and neck;Head & Neck;2024-07-27

3. The efficacy of docetaxel, cisplatin, and 5-fluorouracil chemotherapy in recurrent head and neck squamous cell carcinoma. Report of a case and review of the literature;Oral Oncology;2024-07

4. The use of cetuximab for oral cancer and adverse events with different treatment regimens: A single‐center retrospective study over an 11‐year period;Oral Science International;2024-06-09

5. A phase II trial of paclitaxel plus biweekly cetuximab for patients with recurrent or metastatic head and neck cancer previously treated with both platinum-based chemotherapy and anti-PD-1 antibody;ESMO Open;2024-06